Preclinical evaluation of implantable materials: conventional approaches, new models and future directions.

Fiche publication

Date publication

juillet 2023

Journal

Frontiers in bioengineering and biotechnology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FRISCH Benoit , Dr HEURTAULT Béatrice , Dr LAVALLE Philippe

Tous les auteurs :
Frisch E, Clavier L, Belhamdi A, Vrana NE, Lavalle P, Frisch B, Heurtault B, Gribova V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37576997

Résumé

Nowadays, implants and prostheses are widely used to repair damaged tissues or to treat different diseases, but their use is associated with the risk of infection, inflammation and finally rejection. To address these issues, new antimicrobial and anti-inflammatory materials are being developed. Aforementioned materials require their thorough preclinical testing before clinical applications can be envisaged. Although many researchers are currently working on new tissues for drug screening and tissue replacement, models for evaluation of new biomaterials are just emerging and are extremely rare. In this context, there is an increased need for advanced models, which would best recapitulate the environment, limiting animal experimentation and adapted to the multitude of these materials. Here, we overview currently available preclinical methods and models for biological evaluation of new biomaterials. We describe several biological tests used in biocompatibility assessment, which is a primordial step in new material's development, and discuss existing challenges in this field. In the second part, the emphasis is made on the development of new 3D models and approaches for preclinical evaluation of biomaterials. The third part focuses on the main parameters to consider to achieve the optimal conditions for evaluating biocompatibility; we also overview differences in regulations across different geographical regions and regulatory systems. Finally, we discuss future directions for the development of innovative biomaterial-related assays: models, dynamic testing models, complex multicellular and multiple organ systems, as well as patient-specific personalized testing approaches.